Volume 46, Issue 4, Pages (October 2004)

Slides:



Advertisements
Similar presentations
Volume 118, Issue 3, Pages (March 2000)
Advertisements

The PSA Era is not Over for Prostate Cancer
Volume 53, Issue 3, Pages (March 2008)
Fig. 5. The measurement of phosphorylation of p53 level in N2A cells under high glucose condition and agmatine treatment. (A, B) p53 phosphorylation levels.
Volume 41, Issue 3, Pages (March 2002)
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Volume 70, Issue 1, Pages (July 2016)
Volume 52, Issue 2, Pages (August 2007)
Effect of lysine antifibrinolytics and cyclooxygenase inhibitors on the proteolytic profile of breast cancer cells interacting with macrophages or endothelial.
Volume 61, Issue 5, Pages (May 2012)
Volume 54, Issue 3, Pages (September 2008)
Volume 64, Issue 4, Pages (October 2013)
Volume 71, Issue 4, Pages (April 2017)
Histologic Grading of Noninvasive Papillary Urothelial Neoplasms
Volume 54, Issue 1, Pages (July 2008)
Volume 59, Issue 1, Pages (January 2011)
Volume 53, Issue 5, Pages (May 2008)
Volume 42, Issue 4, Pages (October 2002)
Let the Games Begin (with EAU Approval)
Volume 73, Issue 5, Pages (May 2018)
Volume 68, Issue 1, Pages (July 2015)
Volume 45, Issue 4, Pages (April 2004)
Volume 49, Issue 6, Pages (June 2006)
Daily Administration of Phosphodiesterase Type 5 Inhibitors for Urological and Nonurological Indications  Anthony J. Bella, Ling X. DeYoung, Mussa al-Numi,
The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.
Volume 54, Issue 4, Pages (October 2008)
Prostate Cancer Detection: A View of the Future
CEACAM1: A Novel Urinary Marker for Bladder Cancer Detection
Volume 58, Issue 1, Pages (July 2010)
P.M.J. Moonen, L.A.L.M. Kiemeney, J.A. Witjes  European Urology 
Protective effects of protein kinase C during myocardial ischemia require activation of phosphatidyl-inositol specific phospholipase C  Mamoru Munakata,
Volume 64, Issue 4, Pages (October 2013)
Transient Receptor Potential Vanilloid-1 Signaling as a Regulator of Human Sebocyte Biology  Balázs I. Tóth, Tamás Géczy, Zoltán Griger, Anikó Dózsa,
Volume 70, Issue 1, Pages (July 2016)
Volume 118, Issue 3, Pages (March 2000)
Shaheen Alanee, Kasmintan Schrader, Kenneth Offit  European Urology 
Volume 46, Issue 5, Pages (November 2004)
International Society of Urological Pathology Grading and Other Prognostic Factors for Renal Neoplasia  Brett Delahunt, John R. Srigley, Lars Egevad,
The PSA Era is not Over for Prostate Cancer
Volume 44, Issue 2, Pages (February 2006)
Volume 50, Issue 3, Pages (September 2006)
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
István Borbíró, Erika Lisztes, Balázs I
Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia
Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: Activation of the mitochondria-dependent death-signaling.
Volume 132, Issue 5, Pages (May 2007)
Volume 43, Issue 2, Pages (February 2003)
Volume 46, Issue 4, Pages (October 2004)
Volume 47, Issue 1, Pages (January 2005)
The Economic Costs of Overactive Bladder in Germany
Karl-Dietrich Sievert, Bastian Amend, Arnulf Stenzl  European Urology 
Volume 50, Issue 5, Pages (November 2006)
Volume 53, Issue 6, Pages (June 2008)
Translocation of protein kinase C isoforms is involved in propofol-induced endothelial nitric oxide synthase activation  L. Wang, B. Wu, Y. Sun, T. Xu,
Morphine tolerance increases [3H]MK-801 binding affinity and constitutive neuronal nitric oxide synthase expression in rat spinal cord  Chih-Shung Wong,
Tamás Géczy, Attila Oláh, Balázs I. Tóth, Gabriella Czifra, Attila G
Volume 115, Issue 1, Pages (July 1998)
Prognostic Impact of Comorbidity in Patients with Bladder Cancer
Volume 41, Issue 4, Pages (October 2004)
Volume 120, Issue 1, Pages (January 2001)
European Urology is “Your” Journal
M. Cucchiarini, H. Madry, E.F. Terwilliger 
Volume 52, Issue 4, Pages (October 2007)
Volume 53, Issue 2, Pages (February 2008)
Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma  Jan Roigas  European Urology Supplements  Volume.
Annika Berntsen, Poul F. Geertsen, Inge Marie Svane  European Urology 
Volume 69, Issue 8, Pages (April 2006)
Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas 
Raghvendra Singh, Stelios T Andreadis  Molecular Therapy 
Volume 51, Issue 5, Pages (May 2007)
Presentation transcript:

Volume 46, Issue 4, Pages 462-465 (October 2004) Tumor Grade-Dependent Alterations in the Protein Kinase C Isoform Pattern in Urinary Bladder Carcinomas  Attila Varga, Gabriella Czifra, Béla Tállai, Tamás Németh, Ilona Kovács, László Kovács, Tamás Bı́ró  European Urology  Volume 46, Issue 4, Pages 462-465 (October 2004) DOI: 10.1016/j.eururo.2004.04.014

Fig. 1 Alterations in the PKC isoform patterns in urinary bladder carcinomas of various tumor grades. Epithelial tissues of normal urinary bladder (control, C) and transitional carcinomas with various tumor grades (G) were collected, processed in protease inhibitor containing lysis buffer, and vigorously equal amounts of protein were subjected to SDS-PAGE to perform Western blot analysis of the PKC isoforms as described under “Materials and methods”. (A) Representative Western blot data of several determinations yielding similar results. (B) The amounts of the expressed PKC isoenzymes were quantitated by densitometry (optical density; OD), and values obtained with the tumor samples were expressed as the percentage of the control samples (normalized OD), regarded as 100% (solid line). Points represent mean±SEM of several independent experiments for each antigen. The ∗ represents significant (p<0.05) differences of OD values of any tumor sample compared to control. The ∗∗ represents significant (p<0.05) differences between the OD values of the G2 or G3 tumors compared to that of the G1 samples. The ∗∗∗ represents significant (p<0.05) differences between the OD values of the G3 tumors compared to that of the G2 samples. European Urology 2004 46, 462-465DOI: (10.1016/j.eururo.2004.04.014)